Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
J.C. Lee
ResearcherPublications, citations & collaboration network
J.C. Lee is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 24 works, 15 citations, an h-index of 2 and an i10-index of 0.
24
Works
15
Citations
2
h-index
0
i10-index
IDs:OpenAlex
How has J.C. Lee's publication output changed over time?
ScholarIQpublication output · 2010–2024
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2024.
1
1
1
1
1
1
1
1
1
1
2010201220142017201820192020202220232024
What are the most-cited papers on J.C. Lee?
ScholarIQmost cited works
Morphological characteristics of the upper airway and pressure drop analysis using 3D CFD in OSA patients
Sung‐Seo Mo, Hyung Taek Ahn, J.C. Lee, Yoo‐Sam Chung, Yoon-Shik Moon, Eung‐Kwon Pae, Sang‐Jin Sung
S122593575. 20105 Citations
132 Epithelial to Mesenchymal Transition Leads to Crizotinib-resistance in H2228 Lung Cancer Cells with EML4-ALK Translocation
J.C. Lee, H.R. Kim, Jin Kyung Rho, Chang‐Min Choi, Soo Hwa Jang, Ying Hong
European Journal of Cancer. 20122 Citations
P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession
J.C. Lee, Chang‐Min Choi, Wonjun Ji, S.H. Kim
Journal of Thoracic Oncology. 20192 CitationsOPEN ACCESS
Randomized Phase Ii Study of Belotecan or Topotecan Chemotherapy As Second-Line Chemotherapy After Platinum-Based First-Line Chemotherapy for Small Cell Lung Cancer
Shinkyo Yoon, D.H. Lee, Chang‐Min Choi, J.C. Lee, Joong Sun Lee, S. Kim
Annals of Oncology. 20141 Citations
P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
J.C. Lee, Sei‐Hoon Yang, Dong Kyu Oh
Journal of Thoracic Oncology. 20181 Citations
Related on ScholarIQ
Asan Medical Center
Institution
Morphological characteristics of the upper airway and pressure drop analysis using 3D CFD in OSA patients
Paper
132 Epithelial to Mesenchymal Transition Leads to Crizotinib-resistance in H2228 Lung Cancer Cells with EML4-ALK Translocation
Paper
P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession
Paper
Randomized Phase Ii Study of Belotecan or Topotecan Chemotherapy As Second-Line Chemotherapy After Platinum-Based First-Line Chemotherapy for Small Cell Lung Cancer
Paper
P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
Paper